Eledon Pharmaceuticals, Inc. (ELDN) Reports $69.7M Cash and Runway Into Q2 2027

As of September 30, 2026, Eledon had $69.7M in cash, equivalents and short-term investments, down from $133.3M on December 31, 2025, and expects funding into Q2 2027. Q3 net loss was $3.9M, including a $17.0M non-cash warrant-liability gain.Material DetailsContext by AI AnalystThis is an early-stag…